Um aplicativo iPhone para a rastreabilidade da ferrugem asiática da soja no Brasil.

RESUMO: A soja é, no Brasil, um dos principais itens da produção agrícola, sendo o país o segundo maior produtor mundial deste grão. Devido ao grande crescimento da produção nas últimas décadas, a soja, tornou-se o foco dos principais órgãos relacionados ao agro-negócio brasileiro. Com a introdução da ferrugem asiática da soja no Brasil, um melhor gerenciamento no combate a essa doença se tornou necessária, sendo assim, criado em setembro de 2004, o Consórcio Antiferrugem surgiu com a finalidade de trazer soluções de manejo e controle da dispersão desta doença no Brasil. Este artigo descreve o desenvolvimento de um aplicativo iPhone, criado para dar suporte ao sistema Web do Consórcio Antiferrugem, como uma ferramenta móvel auxiliando o monitoramento da dispersão e a rastreabilidade da ferrugem asiática da soja no Brasil. ABSTRACT: Soybean is one of the major items of agricultural production in Brazil, being the country the second largest producer of this grain. Due to the large increase in production in recent decades, soybean has become the focus of the main organs related to brazilian agribusiness. With the introduction of Asian soybean rust in Brazil, a better management of this disease became necessary, therefore, created in September 2004, the Consortium Antirust emerged with the purpose to bringing solutions to help manage and control the spread of this disease in Brazil. This article describes the development of an iPhone application, designed to support the Antirust Consortium Web System as a mobile tool to assist on monitoring and tracking the dispersion of soybean rust in Brazil.Trabalho apresentado no III Simpósio de Computação Aplicada, Passo Fundo, 2011

Mobilidade e a rastreabilidade da ferrugem asiática da soja no Brasil.

A ferrugem asiática da soja, causada pelo fungo Phakopsora pachyrhizi possui fácil disseminação e pode causar perdas de 30% à 75% na produção. O monitoramento da ferrugem e sua identificação nos estádios iniciais são essenciais para um controle eficiente (YORINORI, 2005). Afim de permitir uma rápida visualização sobre a dispersão desta doença no Brasil, foi desenvolvida uma versão móvel para a plataforma iOS do sistema Web do Consórcio Antiferrugem. O usuário, com o uso do aplicativo em um iPhone, iPod Touch ou iPad, pode ter acesso às informações sobre a dispersão da doença diretamente no seu dispositivo, a qualquer hora e lugar, podendo perceber a aproximação dos focos da doença na sua região e adiantar-se na procura por sinais de infecção na sua lavoura, evitando grandes perdas na produção. O aplicativo traz como diferencial, além da sua mobilidade, a possibilidade de apresentação de informações completas sobre as ocorrências da doença, registradas por laboratórios conveniados ao consórcio. Permite, também, a rastreabilidade sobre a evolução da doença no decorrer das safras, apresentando pontos geolocalizados para os focos da doença. O aplicativo foi desenvolvido sob uma arquitetura de serviços disponíveis na plataforma Web do Consórcio Antiferrugem. Desde que foi disponibilizado, o aplicativo já foi baixado centenas de vezes por usuários do mundo todo, deixando claro o interesse pelas informações não só por produtores e técnicos brasileiros, mas também pelo mercado comprador de soja. Objetivando proporcionar maior agilidade na disseminação das informações, suporte a tecnologia push, para notificações automáticas, está sendo implementado e disponibilizado na loja de aplicativos da Apple (APPLE, 2011).SBIAGRO

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Trastuzumab prolongs survival in HER2 positive breast cancer patients. However, resistance remains a challenge. We have previously shown that ADAM17 plays a key role in maintaining HER2 phosphorylation during trastuzumab treatment. Beside ADAM17, ADAM10 is the other well characterized ADAM protease responsible for HER ligand shedding. Therefore, we studied the role of ADAM10 in relation to trastuzumab treatment and resistance in HER2 positive breast cancer. ADAM10 expression was assessed in HER2 positive breast cancer cell lines and xenograft mice treated with trastuzumab. Trastuzumab treatment increased ADAM10 levels in HER2 positive breast cancer cells (p ≤ 0.001 in BT474; p ≤ 0.01 in SKBR3) and in vivo (p ≤ 0.0001) compared to control, correlating with a decrease in PKB phosphorylation. ADAM10 inhibition or knockdown enhanced trastuzumab response in naïve and trastuzumab resistant breast cancer cells. Trastuzumab monotherapy upregulated ADAM10 (p ≤ 0.05); and higher pre-treatment ADAM10 levels correlated with decreased clinical response (p ≤ 0.05) at day 21 in HER2 positive breast cancer patients undergoing a trastuzumab treatment window study. Higher ADAM10 levels correlated with poorer relapse-free survival (p ≤ 0.01) in a cohort of HER2 positive breast cancer patients. Our studies implicate a role of ADAM10 in acquired resistance to trastuzumab and establish ADAM10 as a therapeutic target and a potential biomarker for HER2 positive breast cancer patients

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

PURPOSE: To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC). METHODS:Thirteen oestrogen receptor-positive, postmenopausal, T2-4, N0-1 BC patients received the LCS combination for 6 months. In these patients we examined the pharmacokinetics of sorafenib and cyclophosphamide, toxicity of the regimen, the clinical response to therapy and changes in the levels of biologically relevant biomarkers. RESULTS:Adequate plasma concentrations of sorafenib were achieved in patients when it was dosed in combination with L+C. The mean plasma concentrations of C were consistently lower following administration of LCS, compared with administration of L+C only. The most common drug-related grade 3/4 adverse events were skin rash (69.3%), hand-foot skin reaction (69.3%) and diarrhoea (46.1%). According to RECIST Criteria, a clinical complete response was observed in 6 of 13 patients. A significant reduction in tumour size, evaluated with MRI, was also observed between baseline and 14 days of treatment in all 13 patients (P=0.005). A significant reduction in SUV uptake, measured by (18)FDG-PET/CT, was observed in all patients between baseline and 30 days of treatment (P=0.015) and between baseline and definitive surgery (P=0.0002). Using modified CT Criteria, a response was demonstrated in 8 out of 10 evaluable patients at 30 days and in 11 out of 13 evaluable patients at the definitive surgery. A significant reduction in Ki67 expression was observed in all patients at day 14 compared with baseline (P<0.00001) and in 9 out of 13 patients at the definitive surgery compared with baseline (P<0.03). There was also a significant suppression of CD31 and VEGF-A expression in response to treatment (P=0.01 and P=0.007, respectively).CONCLUSIONS:The LCS combination is feasible and tolerable. The tumour response and target biomarker modulation indicate that the combination is clinically and biologically active

Examining the effects of adjuvant chemotherapy on cognition and the impact of any cognitive impairment on quality of life in colorectal cancer patients: study protocol

Background: Research suggests that chemotherapy can cause deficits in both patients’ objectively measured and self-reported cognitive abilities which can in turn affect their quality of life (QoL). The majority of research studies have used post-treatment retrospective designs or have not included a control group in prospective cohorts. This has limited the conclusions that can be drawn from the results. There have also been a disproportionate number of studies focussed on women with breast cancer, which has limited the generalisability of the results to other cancer populations. Aim: This study aims to identify the extent and impact of chemotherapy-induced cognitive decline in colorectal cancer patients. Possible associations with poorer QoL will also be explored. Design: This will be a longitudinal controlled cohort study. Questionnaires measuring subjective cognitive functioning, QoL, fatigue and mood, and neuropsychological assessments of objective cognitive function will be collected pre-, mid- and post- chemotherapy treatment from a consecutive sample of 78 colorectal cancer patients from five London NHS Trusts. A further 78 colorectal cancer surgery only patients will be assessed at equivalent time points; this will allow the researchers to compare the results of patients undergoing surgery, but not chemotherapy against those receiving both treatments. Pre- and post-chemotherapy difference scores will be calculated to detect subtle changes in cognitive function as measured by the objective neuropsychological assessments and the self-reported questionnaires. A standardised zscore will be computed for every patient on each neuropsychological test, and for each test at each time point. The post-chemotherapy score will then be subtracted from the pre-chemotherapy score to produce a relative difference score for each patient. ANCOVA will be used to compare mean difference z-scores between the chemotherapy and surgery-only groups while controlling for the effects of gender, age, depression, anxiety, fatigue and education. Discussion: The result from this study will indicate whether a decline in cognitive functioning can be attributed to chemotherapy or to disease, surgical or some other confounding factor. Identification of risk factors for cognitive deficits may be used to inform targeted interventions, in order to improve QoL and help patients’ cope

Definitions and pathophysiology of vasoplegic shock.

Vasoplegia is the syndrome of pathological low systemic vascular resistance, the dominant clinical feature of which is reduced blood pressure in the presence of a normal or raised cardiac output. The vasoplegic syndrome is encountered in many clinical scenarios, including septic shock, post-cardiac bypass and after surgery, burns and trauma, but despite this, uniform clinical definitions are lacking, which renders translational research in this area challenging. We discuss the role of vasoplegia in these contexts and the criteria that are used to describe it are discussed. Intrinsic processes which may drive vasoplegia, such as nitric oxide, prostanoids, endothelin-1, hydrogen sulphide and reactive oxygen species production, are reviewed and potential for therapeutic intervention explored. Extrinsic drivers, including those mediated by glucocorticoid, catecholamine and vasopressin responsiveness of the blood vessels, are also discussed. The optimum balance between maintaining adequate systemic vascular resistance against the potentially deleterious effects of treatment with catecholamines is as yet unclear, but development of novel vasoactive agents may facilitate greater understanding of the role of the differing pathways in the development of vasoplegia. In turn, this may provide insights into the best way to care for patients with this common, multifactorial condition

The spatial structure of lithic landscapes : the late holocene record of east-central Argentina as a case study

Fil: Barrientos, Gustavo. División Antropología. Facultad de Ciencias Naturales y Museo. Universidad Nacional de La Plata; ArgentinaFil: Catella, Luciana. División Arqueología. Facultad de Ciencias Naturales y Museo. Universidad Nacional de La Plata; ArgentinaFil: Oliva, Fernando. Centro Estudios Arqueológicos Regionales. Facultad de Humanidades y Artes. Universidad Nacional de Rosario; Argentin

A922 Sequential measurement of 1 hour creatinine clearance (1-CRCL) in critically ill patients at risk of acute kidney injury (AKI)

Meeting abstrac